- Zacks•16 hours ago
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
- Associated Press•yesterday
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
- The Wall Street Journal•yesterday
Novartis lower-priced replica of Amgen’s rheumatoid arthritis and psoriasis drug Enbrel has been approved in the U.S. to treat multiple inflammatory diseases, the company said.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||169.00 x 100|
|Ask||173.00 x 200|
|Day's Range||169.82 - 171.39|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.40|
|Avg Vol (3m)||2,880,458|
|Dividend & Yield||4.00 (2.33%)|